

Cancer Drug Resistance

[CDR, ISSN 2578-532X (Online)]

is a gold open access international journal founded in 2018 by OAE Publishing Inc. Journal Homepage



Twitter

LinkedIn

WeChat Account

Editor-in-Chief: Godefridus J. (Frits) Peters, Amsterdam University Medical Centers (Amsterdam UMC), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Co-Editor-in-Chief: Yehuda G. Assaraf, Technion-Israel Institute of Technology, Haifa, Israel.


Editorial Board: 52 scientists from 11 countries or regions

Aims and Scope: The journal publishes research articles, reviews, commentaries, perspectives, and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance.

Indexing: ESCI, PubMed Central (PMC), Scopus, CAS, CNKI, Dimensions, Lens, Embase

Journal Metric and Ranking: **Impact Factor (IF): 4.6, JCR Q1 (ONCOLOGY); CiteScore: 6.6, Q1 [Pharmacology (medical)]**

Spotlight on cutting-edge pharmacological findings on cancer drug resistance and its reversal




OPEN ACCESS

ISSN: 2578-532X (Online)


Cancer Drug Resistance

OAE
www.oaepublish.com


www.oaepublish.com
OAE



Dr. Mark Pegram
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.



Dr. Murali M. Yallapu
School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.
Dr. Pallabita Chowdhury
Plough center for Sterile Drug Delivery Systems, The University of Tennessee Health Science Center, Memphis, TN, USA.



Prof. Ning Li
Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Dr. Shuhang Wang
Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.



Dr. Michael M. Gottesman, Dr. Robert W. Robey, and Dr. Suresh V. Ambudkar
Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

OAE
Open Access with Excellence

CDR
Cancer Drug Resistance

Contact us:

Managing Editor: Louise Pan Louise@cdrjournal.com

Editorial Office: editorial@cdrjournal.com

Journal Homepage: <https://www.oaepublish.com/cdr>

Editorial Board

Editor-in-Chief



Godefridus J. (Frits) Peters

Amsterdam University Medical Centers (Amsterdam UMC), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Co-Editor-in-Chief



Yehuda G. Assaraf

Technion-Israel Institute of Technology, Haifa, Israel.

Associate Editors



Elisa Giovannetti

Cancer Center Amsterdam, Amsterdam University Medical Centers (Amsterdam UMC), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, Pisa, Italy.



Paola Perego

Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.



Chiara Riganti

Department of Oncology, University of Torino, Torino, Italy.



Liwu Fu

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.



Hailin Tang

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Publication Information

- **Publication Model:** The journal follows an Open Access (OA) continuous publication model. Articles are indexed in PubMed Central (PMC), Web of Science, and Scopus as soon as they are published.
- **Publication Timeline:** The average time from submission to publication is 100 days.
- **Article Processing Charge (APC):** \$2,400 per article

Featured Articles

Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

Correspondence to: Prof. William H. Gmeiner, Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest University School of Medicine, USA.



Mitochondria in colorectal cancer stem cells- a target in drug resistance

Correspondence to: Prof. Mateus de Almeida Rainho, Laboratory of Stem Cell Research, Histology and Embryology Department, Roberto Alcantara Gomes Biology Institute, State University of Rio de Janeiro, Brazil.



Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

Correspondence to: Dr. Kun Chen, Beijing Chaoyang Emergency Medical Rescuing Center, China; Prof. JianLiang Shen, School of Ophthalmology & Optometry, School of Biomedical Engineering, Wenzhou Medical University, Zhejiang, China.



Mechanisms involved in cancer stem cell resistance in head and neck cell carcinoma

Correspondence to: PhD. Maria Fernanda Setúbal Destro Rodrigues, Biophotonics Applied to Health Sciences, Nove de Julho University, Brazil.



Mechanisms of chemotherapy resistance in ovarian cancer

Correspondence to: Dr. Sachi Horibata, Precision Health Program, Department of Pharmacology and Toxicology, Michigan State University, USA.



Venetoclax resistance: mechanistic insights and future strategies

Correspondence to: Prof. Dr. Marina Y. Konopleva, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

